Openbookopenbook
Equity
Travere Therapeutics Inc(TVTX)
USD --+0.00%
Reward58Moderate
Risk50Moderate
📊75%Data
Thin -5% profit margin · Revenue growing 73% YoY
TVTX
+0.0 · +0.00%
USD · NASDAQ
Travere Therapeutics Inc | Healthcare
Profitless Growth
Market Cap:2.67Bn
ℹ️
Reward Rating
58
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
50
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on TVTX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $42.71.

What is Travere Therapeutics Inc?

, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.

TVTX · Verdict

Solid reward · moderate risk

TVTX's standout is growth; valuation and balance sheet weigh on the picture.

Based on 88% data coverage

TVTX · Verdict

What’s working & what to watch

Strengths 1

  • Growth78/100

    Rev +64.9% CAGR · earnings -43.5%

Watchouts 3

  • Valuation40/100

    P/E 45.5× · PEG 0.27

  • Balance sheet43/100

    Net debt/EBITDA 10.6×

  • Profitability44/100

    -10% net margin · -58% ROE

Model-based scoring. For information only — not financial advice.

What is Travere Therapeutics Inc?

, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.67B.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (58)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap2.67B
P/E RatioN/A
Dividend YieldN/A
52 Week High42.13
52 Week Low12.91
Last AnnualDecember
IPO Date11/8/2012
IncorporatedUSA
Shares Outstanding89M
No. of Employees497
IndustryBiotechnology
ExchangeNASDAQ
Beta0.808
CurrencyUSD
Websitetravere.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.